Abstracts tagged "Drug toxicity"

Abstract Number: 2118 • ACR Convergence 2025
Risks of Fracture in Current and Previous Anticonvulsant Users, An Observational Study
Grace Hyeyeon Lee¹, Hamzah Amin² and marwan Bukhari¹, ¹University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom, ²Lancaster University, Lancaster, United Kingdom
Background/Purpose: Anticonvulsants are commonly used to manage neurological and psychiatric disorders such as epilepsy, migraines and bipolar disorder. These medications are often prescribed long-term, and…
Abstract Number: 1098 • ACR Convergence 2025
Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Francisco Arias¹, Omar Hamdan², Asim Khanfar³, Kristel Barturen⁴ and Roa’a Alshajrawi⁵, ¹University of Texas Rio Grande Valley, McAllen, TX, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Rochester, NY, ⁴Universidad San Martin de Porres, McAllen, TX, ⁵University of Jordan, Amman, 'Amman, Jordan
Background/Purpose: Apremilast, a PDE-4 inhibitor, is commonly indicated for patients with psoriasis as well as Behçet’s disease. Although this medication is generally well tolerated, numerous…
Abstract Number: 2112 • ACR Convergence 2025
Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.
Esther Monleon Acosta¹, Alicia Pérez González², José Andrés Rodríguez Fernández², Pedro José Manuel Hernández², María del Rosario Oliva Ruiz², José María Andreu Ubero², Paloma Valentina Castillo Dayer², Gloria Albaladejo Paredes³, Carlos Fernández Díaz⁴, Angela Egea Fuentes², Montserrat Fernández Salamanca² and Vicente Cogolludo Campillo⁵, ¹Hospital Santa Lucia, Cartagena, Spain, ²Hospital General Universitario Santa Lucia, Cartagena, Spain, ³Hospital General Universitario Santa Lucía, CARTAGENA, Spain, ⁴H.U. Santa Lucia, Murcia, Spain, ⁵Hospital General Universitario Santa Lucia, Santa Lucia, Cartage, Spain
Background/Purpose: Osteonecrosis of the jaw (ONJ) is defined as avascular necrosis of bone located in the maxillofacial region with the presence of exposed bone or…
Abstract Number: 1097 • ACR Convergence 2025
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Elvis Hysa¹, Andrea Casabella², Emanuele Gotelli³, Rosanna Campitiello⁴, Carlo Genova⁴, Enrica Teresa Tanda⁴, Carmen Pizzorni⁵, Alberto Sulli⁵, Vanessa Smith⁶, Marco Amedeo Cimmino⁷, Sabrina Paolino⁵ and Maurizio Cutolo⁴, ¹University of Genoa, Genoa, Italy, ²IRCCS Ospedale Policlinico San Martino, Genova, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genova, Genova, Italy, ⁵University of Genoa, Genova, Italy, ⁶Ghent University Hospital, Gent, Belgium, ⁷Rheumatology Outpatient Clinic, Villa Ravenna, Chiavari, Italy, Genova, Italy
Background/Purpose: An altered immune tolerance disturbed by immune checkpoint inhibitors (ICIs) may contribute to new-onset polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in treated…
Abstract Number: 1985 • ACR Convergence 2025
Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement
Rachel Galvao, Anokhi Saklecha, Julia Stevenson, Ritche Hao, Eugenia Chock and Abhijeet Danve, Yale University, New Haven, CT
Background/Purpose: Teratogenic medications are commonly prescribed to women of reproductive age who have rheumatic conditions. Counseling on teratogenicity and contraception is critical to reducing patients’…
Abstract Number: 1092 • ACR Convergence 2025
Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Binod Kc¹, Aakritee Sharma Subedi¹, Salome Walsh¹, Areeba Memon¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the immune system's ability to fight cancer. However, their use is associated with immune-related…
Abstract Number: 1979 • ACR Convergence 2025
Utility of ALT/AST and Fibrosis-4 Index (FIB-4) Score in Monitoring Methotrexate Hepatotoxicity in Rheumatologic Disease: A Retrospective Analysis
Julia Wajsberg¹, Dana Nachawati², Lenche Kostadinova³, Donald Anthony⁴ and Maya Mattar³, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland, ³Louis Stolkes Cleveland VA, Cleveland, ⁴The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Methotrexate (MTX) is widely used in rheumatologic disease but carries hepatotoxic risk. Standard monitoring relies on measurement of alanine and aspartate aminotransferase (ALT and…
Abstract Number: 1089 • ACR Convergence 2025
Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Alice Tison¹, Deanna Jannat-Khah², Laura Cappelli³ and Anne R. Bass², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Inflammatory arthritis (IA)- and polymyalgia rheumatica (PMR)-like syndromes occur in about 6% of patients receiving an immune checkpoint inhibitor (ICI) and can worsen quality…
Abstract Number: 1913 • ACR Convergence 2025
Do We Screen For and Do We Miss Antimalarial-Induced Cardiomyopathy (AMIC)? Risk Profiles according to Hydroxychloroquine Exposure Duration
Youngmin Kim¹, Robert Padera², Brittany Weber³ and Karen H. Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, DEDHAM, MA, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for autoimmune diseases but carries a risk of antimalarial-induced cardiomyopathy (AMIC) that increases with long-term use and is often…
Abstract Number: 1088 • ACR Convergence 2025
Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Alice Tison¹, Deanna Jannat-Khah², Laura Cappelli³ and Anne R. Bass², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: The broad use of immune checkpoint inhibitors (ICIs) in oncology has led to the emergence of ICI-induced inflammatory arthritis (ICI-IA). The aim of this…
Abstract Number: 1886 • ACR Convergence 2025
Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: High-risk medications (HRMs) may increase the risk of adverse events such as falls and fractures, hospitalizations, hospital length of stay, and death in older…
Abstract Number: 1048 • ACR Convergence 2025
Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
Malika Ibrahim¹, Samuel Good², Victor Tran³, David Chetrit⁴, Michael McClean⁵, Myung Shin Sim⁶, Hannah Kang¹, Jennifer Barton⁷, Meika Fang⁸, Angelo Gaffo⁹, fadi Hage¹⁰, cynthia Jackevicius⁵, Michael Pillinger¹¹, gabriela Schmajuk¹², Jasvinder Singh¹³, Alberta Warner¹⁴, Neal Yaun¹⁵ and John FitzGerald¹⁶, ¹David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, CA, ³David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Costa Mesa, CA, ⁴Carolina Health Specialists, Myrtle Beach, SC, ⁵Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, ⁶West LA VA Medical Center, Los Angeles, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ¹⁰VA Birmingham health care, Birmingham, AL, ¹¹New York University Grossman School of Medicine, New York,, NY, ¹²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ¹³Baylor College of Medicine, Houston, TX, ¹⁴VA Greater Los Angeles/UCLA, Los Angeles, ¹⁵UCSF / SFVA, San Francisco, ¹⁶UCLA, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for rheumatic diseases, but data on its cardiac safety, particularly QTc prolongation, remains limited. Concerns about HCQ inducing QTc…
Abstract Number: 1735 • ACR Convergence 2025
Endocrine Disruptors Exacerbates Osteoarthritis Pain And Inflammation
Elise Herardot¹, Nadine Soliman¹, Audrey Pigenet¹, Ilana Slotine¹, Anni Herranan², Samia Bahieddine¹, Jean-Baptiste Fini², Olivier Tabary¹, Adeline Cambon³, Xavier HOUARD⁴, Francis BERENBAUM⁵, SELLAM JEREMIE⁶ and Alice Courties⁷, ¹Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, Paris, France, ²UMR ⁷²²¹, Phyma, CNRS–Muséum National d’Histoire Naturelle, Sorbonne Université, ⁷⁵⁰⁰⁵ Paris, France, Paris, France, ³Department of Orthopedic, Trauma and Hand Surgery, Hôpital Saint-Antoine, Sorbonne University, ¹⁸⁴ Rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France, Paris, France, ⁴Centre de Recherche Saint-Antoine, UMR_S⁹³⁸ INSERM /Sorbonne Université, Paris, France, PARIS, France, ⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ⁶Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France, ⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹², Paris, France / Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France, Paris, France
Background/Purpose: Osteoarthritis (OA) affects over 590 million individuals globally. Epidemiological data suggest that exposure to environmental pollutants, particularly endocrine-disrupting chemicals (EDCs) such as phthalates, PFAS,…
Abstract Number: 0670 • ACR Convergence 2025
Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis
Zahraa Qamhieh¹, Dalia Sriwi¹, Callie Saric², Tripti Singh³, Christie Bartels⁴ and Shivani Garg⁵, ¹University of Wisconsin, Madison, Department of Medicine, Madison, WI, ²University of Wisconsin, Madison, School of Medicine and Public Health, Madison, WI, ³University of Wisconsin, Madison, Department of Nephrology, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Clinical response to Mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug monitoring (TDM) of MPA could help improve treatment efficacy. Our objective in…
Abstract Number: 1731 • ACR Convergence 2025
A Post-Marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-Cell Therapy Using the FDA Adverse Event Reporting System
Malvika Gupta¹, Christopher Graham² and Supriya Gupta³, ¹Mayo Clinic, Rochester MN, Rochester, MN, ²University of Minnesota, Minneapoils, MN, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Chimeric Antigen Receptor (CAR-T) therapy has transformed the management of hematologic cancers, with multiple products approved by the U.S. Food and Drug Administration (FDA).…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].